Enfermedad hepática en pandemia: ¿cómo sospecharla y tratarla?

Gisela Romero, Edgardo Mengual-Moreno

Resumen


Para Diciembre de 2019, las autoridades de salud de China reportaron 27 casos de neumonía inusual, con falla respiratoria y muerte. En Enero 2020, los científicos chinos confirmaron que dichos casos era debido a un nuevo coronavirus que se denominó SARS-CoV-2. Los estudios revelaron que más del 80% del material genético de este virus presenta homología con coronavirus de murciélagos. Entre el 1% al 11% de los pacientes con Síndrome Respiratorio Agudo Severo por SARS-CoV2 pueden tener enfermedad hepática crónica de base, por lo que es necesario comprender las interacciones entre la infección y enfermedad hepática subyacente para el manejo clínico. Los mecanismos responsables del daño hepático no son bien conocidos y pueden ser multifactoriales.

Palabras clave


SARS-CoV-2, enfermedad hepática, drogas, cirrosis, autoinmunidad, Hepatitis B, Hepatitis C.

Texto completo:

PDF

Referencias


Ahn D, Shin H, Kim M, Lee S, Kim H, Myoung J, et al. Current Status of Epidemiology, Diagnosis, Therapeutics,

and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol 2020;30(3):313-324.

Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis 2020;39(6):1011-1019.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382(18):1708-1720.

Williamson E, Walker A, Bhaskaran K, Bacon S, Bates C, Morton C, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584(7821):430-436.

Harrison S, Fazio E, Lane D, Underhill P, Lip G. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med 2020;17(9):e1003321.

Lai C, Shih T, Ko W, Tang H, Hsueh P. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020;55(3):105924.

Riou J, Althaus C. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill 2020;25(4):2000058.

Lotfi M, Hamblin M, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta 2020;508:254-266.

Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology 2020;158(6):1518-1519.

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020;324(8):782-793.

Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses 2020;12(4):372.

Bourgonje A, Abdulle A, Timens W, Hillebrands J, Navis G, Gordijn S, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol 2020;251(3):228-248.

Galanopoulos M, Gkeros F, Doukatas A, Karianakis G, Pontas C, Tsoukalas N, et al. COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract. World J Gastroenterol 2020;26(31):4579-4588.

Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020;73(3):566-574.

Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: The current evidence. United European Gastroenterol J 2020 Jun;8(5):509-519.

Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020 May;5(5):428-430.

Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020 May;40(5):998-1004.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507-513.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020;71(15):762-768.

Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical Features of COVID-19-Related Liver Functional Abnormality. Clin Gastroenterol Hepatol 2020;18(7):1561-1566.

Montastruc F, Thuriot S, Durrieu G. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31060-0.

Mantovani A, Beatrice G, Dalbeni A. Coronavirus disease 2019 and prevalence of chronic liver disease: a meta-analysis. Liver Int.

Chen X, Jiang Q, Ma Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 and hepatitis B virus co- infection. medRxiv Available at: https://doi.org/10.1101/2020. 03.23.20040733

Jian Wu, Shu Song, Hong-Cui Cao, Lan-Juan Li. Liver diseases in COVID-19: Etiology, treatment and prognosis. World Journal of Gastroenterology. May 21, 2020 Volume 26 Issue 19

K. Rajender Reddy, M.D. SARS-CoV-2 and the liver: Considerations in Hepatitis B and Hepatitis C infections. | Clinical liver Disease, vol 15, No 5, May 2020.

Tatyana Kushner, M.D., M.S.C.E., * and John Cafardi, M.D. Chronic liver Disease and COviD-19: alcohol Use Disorder/ alcohol-associated liver Disease, nonalcoholic Fatty liver Disease/ nonalcoholic steatohepatitis, autoimmune liver Disease, and Compensated Cirrhosis. Clincal liver Disease, vol 15, No 5, May 2020

Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Australia.

Atit Ghoda , Manoj Ghoda. Liver Injury in COVID-19 Infection: A Systematic Review. Cureus 12(7): e9487. DOI 10.7759/cureus.9487

Farshidpour1 & David Kim2 & Shilpa Junna2 & Juanita Merchant2. A brief review of liver injury in patients with CoronaVirus Disease-19 during the pandemic. Indian Journal of Gastroenterology. Jule 2020

Balla M, Merugu GP, Patel M, et al. COVID-19, Modern pandemic: a systematic review from front-line health care providers' perspective. J Clin Med Res. 2020;12:215–29.

Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382:727–33.

Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections.LiverInt.2020;40:998–1004.

Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, evaluation and treatment coronavirus (COVID-19). Treasure Island (FL): StatPearls Publishing; 2020.

Wang D,Hu B,Hu C,et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323:1061–9.

Huang C,Wang Y,Li X,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. 2020;395: 497–506.




DOI: http://dx.doi.org/10.61155/gen.v74i3.526

VIDEOS GEN



Pseudoquiste pancreático postraumático y Síndrome del Ducto Pacreático Desconectado.
Autor: Dr. Freddy Pereira Graterol

CPRE. Sitio de sección del ducto pancreático principal

Drenaje transgástrico de pseudoquiste pancreático

CPRE. Sección del ducto hepático izquierdo por traumatismo de abdomen





Cavernomatosis portal y colangiopatía portal. A propósito de un caso.
Autora: Dra. Anais Karina García Yaraure
 

Cavernomatosis portal Pre Colocacion de TIPS.

 

Cavernomatosis portal Post Colocacion de TIPS.




 

 

 

 

 

 

LatindexSciELOCrossref

Revista GEN
ISSN: 0016-3503 e-ISSN: 2477-975X
Depósito Legal: pp197602CS570
Sociedad Venezolana de Gastroenterología
Este trabajo está licenciado bajo Creative Commons 4.0.
Revista GEN no almacena ningun tipo de cookies ni variables de sesion de usuarios